Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Human papillomavirus DNA and Pap tests: the need for cotesting in opportunistic setting during the transition time.

Mariani L, Sideri M, Costa S, Cristoforoni P, Origoni M, Preti M; Italian HPV Study Group..

J Low Genit Tract Dis. 2013 Jul;17(3):362-5. doi: 10.1097/LGT.0b013e31826f24c0. No abstract available.

PMID:
23552207
2.

Cervical human papillomavirus testing to triage borderline abnormal pap tests in HIV-coinfected women.

DʼSouza G, Burk RD, Palefsky JM, Massad LS, Strickler HD; WIHS HPV Working Group..

AIDS. 2014 Jul 17;28(11):1696-8. doi: 10.1097/QAD.0000000000000285. No abstract available.

3.

Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting.

Schiffman M, Solomon D.

N Engl J Med. 2013 Dec 12;369(24):2324-31. doi: 10.1056/NEJMcp1210379. Review. No abstract available.

PMID:
24328466
4.

Off-label high-risk HPV DNA testing of vaginal ASC-US and LSIL cytologic abnormalities at Parkland hospital.

Chappell CA, West AM, Kabbani W, Werner CL.

J Low Genit Tract Dis. 2010 Oct;14(4):352-5. doi: 10.1097/LGT.0b013e3181f0b69d.

PMID:
20885164
5.

A new generation of studies of human papillomavirus DNA testing in cervical cancer screening.

Franco EL.

J Natl Cancer Inst. 2009 Dec 2;101(23):1600-1. doi: 10.1093/jnci/djp392. Epub 2009 Nov 9. No abstract available.

PMID:
19903806
6.

Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.

Broccolo F, Fusetti L, Rosini S, Caraceni D, Zappacosta R, Ciccocioppo L, Matteoli B, Halfon P, Malnati MS, Ceccherini-Nelli L.

J Med Virol. 2013 Mar;85(3):472-82. doi: 10.1002/jmv.23487. Epub 2012 Dec 26.

PMID:
23280876
7.

Cervical cancer screening from Pap smear to human papillomavirus DNA testing.

Jin XW, Xu H.

Compr Ther. 2001 Fall;27(3):202-8. Review.

PMID:
11569320
8.

Whatever happened to the annual pap smear?

Vigliani MB.

R I Med J (2013). 2013 Jan 4;96(1):36-8. No abstract available.

PMID:
23638458
9.

Re: Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Lynge E, Rebolj M.

J Natl Cancer Inst. 2010 May 19;102(10):739; author reply 739-40. doi: 10.1093/jnci/djq109. Epub 2010 Apr 1. No abstract available.

PMID:
20360534
10.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
11.

Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).

Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Smith JS.

Gynecol Oncol. 2012 Apr;125(1):175-80. doi: 10.1016/j.ygyno.2012.01.002. Epub 2012 Jan 9.

PMID:
22233689
12.

Detection of human papillomavirus on Papanicolaou-stained cervical smears using indirect in situ polymerase chain reaction hybridization.

Manavi M, Bauer M, Pischinger K, Czerwenka K.

Arch Pathol Lab Med. 2001 Mar;125(3):353-7.

PMID:
11231482
13.

Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.

Ciotti M, Sesti F, Paba P, Benedetto A, Patrizi L, Criscuolo A, Piccione E, Branca M, Syrjänen K, Favalli C.

Eur J Gynaecol Oncol. 2004;25(5):577-84.

PMID:
15493169
14.

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL; Canadian Cervical Cancer Screening Trial Study Group..

N Engl J Med. 2007 Oct 18;357(16):1579-88.

15.

Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens.

Kaliterna V, Lepej SZ, Vince A.

J Med Microbiol. 2009 Dec;58(Pt 12):1662-3. doi: 10.1099/jmm.0.012138-0. Epub 2009 Aug 6. No abstract available.

PMID:
19661205
16.

The modern cytology laboratory: moving beyond the Pap test.

Joste N, Gober-Wilcox J.

Obstet Gynecol Clin North Am. 2013 Jun;40(2):199-210. doi: 10.1016/j.ogc.2013.02.001. Epub 2013 Apr 17.

PMID:
23732025
17.

Hybrid Capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia.

Tan JH, Garland SM, Tabrizi SN, Moore EE, Danielewski JA, Quinn MA.

J Low Genit Tract Dis. 2013 Jul;17(3):308-14. doi: 10.1097/LGT.0b013e31826cd7c1.

PMID:
23552206
19.

Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with Amplicor HPV and Hybrid Capture 2 assays for detection of high-grade lesions of the uterine cervix.

Dufresne S, Sauthier P, Mayrand MH, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F.

J Clin Microbiol. 2011 Jan;49(1):48-53. doi: 10.1128/JCM.01063-10. Epub 2010 Nov 17.

20.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072

Supplemental Content

Support Center